Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02535364 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 study, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- Terminated
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT02535364 is a Phase 2 study that was terminated before completion, run by Juno Therapeutics, a Subsidiary of Celgene. The registered enrollment target is 82 participants.
The verdict
NCT02535364, a Phase 2 study, was terminated before completion, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
This single-arm, multicenter Phase 2 trial will treat adult patients who have relapsed or refractory B-ALL with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor (CAR) that will bind to leukemia cells that express the CD19 protein on the cell surface. The study will determine if these modified T cells (called JCAR015) help the body's immune system eliminate leukemia cells. The trial will also study the safety of treatment with JCAR015, how long JCAR015 cells stay in the patient's body, the extent to which JCAR015 eliminates minimal residual disease, and the impact of this treatment on survival.
Interventions
- BIOLOGICAL JCAR015 (CD19-targeted CAR T cells)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2015-08-21 |
| Est. Completion | 2017-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02535364
The ClinicalTrials.gov registry entry for NCT02535364 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Juno Therapeutics, a Subsidiary of Celgene, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JCAR015 (CD19-targeted CAR T cells) is the first listed.
NCT02535364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02535364 about?
NCT02535364 is a clinical study titled "Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)". This single-arm, multicenter Phase 2 trial will treat adult patients who have relapsed or refractory B-ALL with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor (CAR) that will bind to leukemia cells that express the CD19 protein on ...
What is the current status of trial NCT02535364?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2015-08-21. Estimated completion is 2017-09-01.
What interventions are being tested in trial NCT02535364?
The interventions under investigation include: JCAR015 (CD19-targeted CAR T cells) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02535364?
This trial is sponsored by Juno Therapeutics, a Subsidiary of Celgene, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.